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Significant progresses have been made in genetic research
in MDS. Through RNA interference technology, knock-
down of RPS14 recapitulated the pathological process of
decreased erythropoiesis [1]. Transgenic expression of
RPS14 in 5q- MDS cells rescued the phenotype of insuffi-
cient erythropoiesis. This strongly suggests that haploin-
sufficiency of RPS14 is one of the molecular mechanisms
in the pathogenesis of 5q- MDS. SF3B1 is a core compo-
nent of RNA splicesome and involved in the regulation of
the mitochondrial pathway. In a study of 533 patients (pts)
with MDS, 150 (28.1%) was found to have SF3B1 gene
mutation, which has a positive predictive value of 97.7%
for RARS and correlates well with better overall survival
(OS) and lower risk for AML transformation [2,3].
Hypomethylating therapy represents a significant mile-
stone in myelodysplasia (MDS) management. TET2,
IDH1/2, and DNMT3A are regulators of DNA methyla-
tion [4]. EZH2 and UTX were found to be involved in the
histone H3K26 and H3K27 methylation. ASX1 was found
to be deleted in 11-15% of MDS pts. In a study of 88 pts
with MDS, mutations of DNMT3A, IDH1/2, and TET2
were found to be correlated with responses to azacytidine
/decitabine(64% in mutated vs 35% wild type, P=0.01) [5].
microRNA-21 may also serve as a biomarker for therapy
response to hypomethylating agents in MDS. In a study of
63 pts, lower level of serum miR-21 correlated with higher
PFS and OS (p 0.003 and 0.001, respectively) [6].
In terms of therapy, azacytidine (75 mg /m2 x 5) was
studied in combination with lenalidomide (10 mg x 21) in
36 refractory pts (IPSS=>1.5) . Overall response rate
(ORR) was 71% (CR 40, PR 31) [7]. Azacytidine (75 mg
/m2 x 5 ) was also studied in combination with vorinostat
(200 mg TID x 5) in 30 untreated MDS pts with poor clin-
ical status (Cr>=1.5, Bilirubin >=2.0). ORR was 30% (CR
27%) and OS was 7 months in these high-risk pts
(expected pre-therapy OS <60 days) [8].
Several novel agents were also reported. Oral decitabine
was reported in a phase I bioavailability trial [9]. The oral
decitabine has a bioavailability of 3.9 to 14%. Oral doses of
30- 240 mg in MDS patients had similar safety profiles to
that of the 20 mg /m2 IV administration. RAP-536 was
found to promote erythropoiesis in a mouse model
through an EPO-independent pathway [10]. IRAK1 is a
serine /threonine kinase. miRNA-146a –deficient mice
had IRAK1 overexpression and developed MDS-like phe-
notype. Phosphorylated IRAK1 was higher in MDS
patients. A small molecule inhibitor of IRAK1 was studied
in cell lines and in MDS sample cells. Increased apoptosis
was seen in these cells. Interestingly, IRAK1 inhibitor
spared the normal CD34+ cells [11].
Iron chelation therapy is increasingly used in MDS
pts, especially when MDS patients are living longer with
the current therapies. Retrospective analysis of iron che-
lation therapy in MDS pts was reported from Italy and
Canada [12,13]. However, the efficacy in MDS cannot
be clearly ascertained since there is no randomized pro-
spective study specifically addressing this issue.
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